Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Is the Nerve Growth Factor (NGF) a Useful Biomarker in Neurogenic Bladder Dysfunction After Spinal Cord Injury?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02138149
Recruitment Status : Completed
First Posted : May 14, 2014
Last Update Posted : November 17, 2015
Sponsor:
Information provided by (Responsible Party):
Swiss Paraplegic Centre Nottwil

Brief Summary:

Spinal cord injury (SCI) almost always affects bladder function as well. As a result of this bladder dysfunction, individuals with SCI have to undergo regular invasive examination of their bladder function (urodynamic examination).

The nerve growth factor (NGF) is released from smooth muscle cells of the bladder, and there are reports, that the concentration of NGF is elevated in the urine of patients with bladder dysfunction. The NGF concentration can also be measured in the blood. The concentration of NGF in the blood and urine of SCI individuals has not yet been investigated. These concentrations may correlate with the severity of bladder dysfunction, and may thus be used to replace or at least reduce the number of the more invasive urodynamic examinations.

The hypothesis that urine and blood NGF concentrations in individuals with SCI are higher compared to individuals with healthy bladder function will be tested.


Condition or disease
Spinal Cord Injury Neurogenic Detrusor Overactivity Neurogenic Lower Urinary Tract Dysfunction

Layout table for study information
Study Type : Observational
Actual Enrollment : 47 participants
Observational Model: Case-Control
Time Perspective: Prospective
Study Start Date : November 2013
Actual Primary Completion Date : November 2015
Actual Study Completion Date : November 2015

Resource links provided by the National Library of Medicine


Group/Cohort
spinal cord injury
individuals with neurogenic lower urinary tract dysfunction
control group
individuals with physiologic bladder function



Primary Outcome Measures :
  1. urinary concentration of nerve growth factor [ Time Frame: day 0 ]

Secondary Outcome Measures :
  1. serum concentration of nerve growth factor [ Time Frame: day 0 ]
  2. demographics [ Time Frame: day 0 ]
  3. urodynamics [ Time Frame: day 0 ]
    only participants with spinal cord injury

  4. International Prostate Symptom Score (I-PSS) [ Time Frame: day 0 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
individuals suffering from neurogenic lower urinary tract dysfunction, namely neurogenic detrusor overactivity
Criteria

Control Group

Inclusion Criteria:

  • physiologic bladder function

Exclusion Criteria:

  • no signed consent form
  • age <18 / >80 years
  • urinary tract infection
  • bladder surgery
  • radiation therapy of the pelvic area
  • pregnancy
  • bleeding disorder

Study Group

Inclusion Criteria:

  • neurogenic detrusor overactivity
  • presentation for urodynamic examination

Exclusion Criteria:

  • no signed consent form
  • age <18 / >80 years
  • urinary tract infection
  • bladder augmentation
  • bladder evacuation by permanent catheterization
  • radiation therapy of the pelvic area
  • pregnancy
  • bleeding disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02138149


Locations
Layout table for location information
Switzerland
Swiss Paraplegic Centre
Nottwil, LU, Switzerland, 6207
Sponsors and Collaborators
Swiss Paraplegic Centre Nottwil
Layout table for additonal information
Responsible Party: Swiss Paraplegic Centre Nottwil
ClinicalTrials.gov Identifier: NCT02138149    
Other Study ID Numbers: 2013-22
First Posted: May 14, 2014    Key Record Dates
Last Update Posted: November 17, 2015
Last Verified: November 2015
Keywords provided by Swiss Paraplegic Centre Nottwil:
spinal cord injury
neurogenic lower urinary tract dysfunction
nerve growth factor
neurogenic detrusor overactivity
urodynamics
Additional relevant MeSH terms:
Layout table for MeSH terms
Spinal Cord Injuries
Urinary Bladder, Overactive
Wounds and Injuries
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Urinary Bladder Diseases
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations